As recently announced in a previous e-blast, on April 15, 2026, the FDA indicated that several peptides would be removed from Category 2 (Bulk Substances that Raise Significant Safety Concerns). This immediately decreases restrictions on the following peptides and the ability to compound pharmacies to produce them.
Here is the list of these peptides.
- BPC-157
• Thymosin Beta-4 Fragment (LKKTETQ)
• Epitalon
• GHK-Cu (injectable)
• MOTS-c
• DSIP (Emideltide)
• Dihexa Acetate
• Ibutamoren Mesylate
• Melanotan II
• KPV
• Semax (heptapeptide)
• Cathelicidin LL-37
These peptides will be brought before the Pharmacy Compounding Advisory Committee (PCAC) at its upcoming meetings, beginning in July. During this process, independent experts will evaluate each peptide based on comprehensive clinical, pharmacological, and safety data.
In this newsletter, Dr. Dominique Fradin-Read reviews one peptide that has generated significant interest: Delta Sleep-Inducing Peptide (DSIP) as many of our patients have been waiting for it.
DSIP
DSIP stands for Delta Sleep-Inducing Peptide, a small naturally occurring peptide that was first discovered in the 1970s by the Swiss Schoenenberger-Monnier group. It is a short peptide of 9 amino acids originally isolated from animal brain extracts (rabbits). It is found in both the brain and peripheral tissues.
Benefits for Sleep
Studies have demonstrated that DSIP can significantly increase delta wave electrical activity in the brain, often increasing it well above baseline levels (e.g., 230% in one study). The peptide not only promotes deep, restorative sleep with increased delta waves; it also modulates sleep-wake cycles by reducing stress-induced interruptions .
Therefore, DSIP peptide acts more as a regulator and modulator of normal sleep than a sedative. It improves sleep efficiency and reduces latency in insomniacs
Benefits for Hormones
Besides its effects on sleep DSIP acts on the neuroendocrine system
- The peptide has been shown to stimulate the release of growth hormone (GH) in some studies, with one study indicating a significant increase of approximately 50% above basal values.
- It influences the hypothalamic-pituitary-adrenal (HPA) axis, acting on cortisol and ACTH levels, which may help normalize stress responses and improve sleep-related hormone modulation.
- Research indicates that DSIP can stimulate the release of LH, which in turn can lead to increased testosterone levels.
Potential Benefits for Chronic Pain
- Research indicates that DSIP can significantly lower pain levels in patients suffering from chronic pain (fibromyalgia in particular), with studies showing efficacy in 6 out of 7 participants in specific trials.
- Mechanism of Action: DSIP is thought to influence opioid receptors at the supraspinal level, which contributes to pain management. It also helps regulate cortisol levels and reduce stress-related conditions.
- Targeted Conditions: It has shown promises for managing pain related to fibromyalgia, arthritis, chronic tinnitus, and headaches, including migraines and vasomotor headaches.
Potential Benefits for Depression
Delta Sleep-Inducing Peptide (DSIP) can indirectly alleviate depression by improving sleep and reducing chronic pain symptoms, particularly stress-related depressive disorders in chronic fatigue patients. It modulates the hypothalamic-pituitary-adrenal (HPA) axis and, while not a standard antidepressant, it may improve sleep quality in patients with mood disorders.
Other Benefits
Researchers have explored intranasal delivery, which is practical for treating neurological conditions like strokes.
DSIP acts as a neuroprotective agent in experimental animal stroke models by improving motor recovery and reducing mortality, primarily through anti-ischemic and anti-oxidative effects. Research shows that intranasal administration can mitigate brain tissue damage and improve neuronal resilience following ischemic stroke.
Anecdotally DSIP demonstrates potential antiepileptic activity by acting as an endogenous modulator of brain excitability, with studies showing it can suppress convulsions and reduce seizure severity in animal models.
It has been postulated that delta sleep-inducing peptide (DSIP) possesses an agonistic activity on opiate receptors and might be of value in the treatment of withdrawal syndromes. In a study DSIP produced a beneficial effect in 48 (22 alcoholics and 26 from 27 opiate addicts), with an immediate onset of action, a good and lasting suspension of the somatic symptoms and signs. Anxiety resolved slowly within hours This peptide could offer a new physiologically based approach for the treatment of established withdrawal syndrome.
Conclusion
DSIP is a biologically intriguing peptide with potential roles in sleep regulation and neuroendocrine function. However, much of the current evidence is preliminary, and many proposed benefits are based on small-scale or preclinical studies.
DSIP represents a shift toward working with the body, not against it—supporting natural rhythms, optimizing recovery, and addressing foundational aspects of health.
As research continues to evolve, peptides like DSIP may redefine how we approach sleep, resilience, and long-term wellness.